Structure Therapeutics in the spotlight

$GPCR's Phase 1b data relative to other obesity names in competitive landscape

Structure Therapeutics (GPCR) is up more than 30% since this morning after announcing Phase 1b data of its oral GLP-1 receptor agonist, GSBR-1290, in overweight patients. At 28 days, Structure’s once-a-day pill showed weight reduction of 4.8kg or approximately 5.4% at the highest dose (90mg).

How Does Data Compare With Other Orals?
In a similar study, Eli…